This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Vanda's Fanapt Deal Just Okay: BioBuzz

ROCKVILLE, Md. ( TheStreet) -- Vanda Pharmaceuticals (VNDA) found a partner willing to sell its schizophrenia drug Fanapt, but is this the deal the company and its shareholders really wanted?

Novartis (NVS) is the logical choice to sell Fanapt in the U.S., probably the only choice, since the Swiss drug maker used to own the Fanapt, licensed the drug to Vanda in 2004 but still controls significant financial rights.

An outright sale of Vanda to Novartis was the deal Vanda bulls dreamed about, which is why the stock traded as high as $16 a share this year.

But Monday's licensing deal is more problematic. The $200 million in cash Vanda receives from Novartis supports a base valuation of about $7 a share, but upside from there is now almost totally dependent on Fanapt sales.

Vanda won't disclose its sales royalty but hinted that it was in the mid-teens range. If you assume 15% and peak Fanapt sales ranging from $200 million to $400 million, Fanapt is worth between $4 a share and $8 a share to Vanda.

Add that to the cash from this licensing deal and Vanda's stock is worth $11-$15 a share.

Vanda shares were up 10% to $12.65 in recent Tuesday trading.

Let's give Vanda credit for its accomplishments. The company got Fanapt approved, a feat no one thought possible. And the company made the best deal possible for the drug's commercialization. Fanapt is launching into a very tough competitive environment for schizophrenia drugs, including lower-cost generics, but if the drug does very well, Vanda stands to gain more from an additional $265 million in milestone payments from Novartis.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs